#6
Recursion Pharmaceuticals AI Platform
Recursion Pharmaceuticals' AI platform, combining robotics and high-content imaging, tests 2.2 million compound-disease combinations per week — a throughput 1,000x greater than traditional drug discovery. This efficiency led to REC-994 for cerebral cavernous malformation entering Phase II trials as the first fully AI-discovered neurological drug candidate.
0
Photos (1)
Comments on "Recursion Pharmaceuticals AI Platform"
Have a take on this ranking?
Comments are how the argument actually happens here. Posting one needs a free account — it takes about a minute.
No comments yet.
The first comment sets the terms of the argument.